CIMDUO
Mylan Pharmaceuticals, Inc
| Research |
OneLook
Acronym Finder
|
| Serial Number | 87418781 |
| Registration Number | 5596590 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Law Office Assigned | L40 |
| Employee Name | MARTIN, CHRISTINE C |
Timeline
| 2017-04-20 | Application Filed |
| 2017-08-22 | Published for Opposition |
| 2018-06-25 | Date of First Use |
| 2018-09-26 | Location: PUBLICATION AND ISSUE SECTION |
| 2018-10-30 | Status: Live/Registered |
| 2018-10-30 | Trademark Registered |
| 2018-10-30 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  Mylan Pharmaceuticals, Inc |
| Address | 781 Chestnut Ridge Road Morgantown WV 26505 |
| Legal Entity Type | Corporation |
| Legal Entity State | WV |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceuticals preparations for the treatment of HIV-1 |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2017-04-24 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2017-04-26 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2017-07-17 | 3 DOCK D:Assigned to Examiner |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2017-07-19 | 4 CNSA P: |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2017-08-02 | 5 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2017-08-22 | 6 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2017-08-22 | 7 NPUB E:E-Mail |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2017-10-17 | 8 NOAM E:E-Mail |
| TEAS EXTENSION RECEIVED | 2018-04-13 | 9 EEXT I:Incoming Correspondence |
| EXTENSION 1 FILED | 2018-04-13 | 10 EXT1 S: |
| EXTENSION 1 GRANTED | 2018-04-13 | 11 EX1G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2018-04-17 | 12 EXRA E:E-Mail |
| TEAS STATEMENT OF USE RECEIVED | 2018-09-04 | 13 EISU I:Incoming Correspondence |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2018-09-25 | 14 AITU A:Allowance for Publication |
| USE AMENDMENT FILED | 2018-09-04 | 15 IUAF S: |
| STATEMENT OF USE PROCESSING COMPLETE | 2018-09-25 | 16 SUPC I:Incoming Correspondence |
| ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2018-09-26 | 17 CNPR P: |
| NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2018-09-27 | 18 SUNA E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2018-10-30 | 19 R.PR A:Allowance for Publication |
| TEAS CHANGE OF OWNER ADDRESS RECEIVED | 2021-11-18 | 20 COAR I:Incoming Correspondence |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2021-11-18 | 21 TCCA I:Incoming Correspondence |
| APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2021-11-18 | 22 CHAN I:Incoming Correspondence |
| COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | 2023-10-30 | 23 REM1 E:E-Mail |
| TEAS SECTION 8 & 15 RECEIVED | 2023-10-30 | 24 E815 I:Incoming Correspondence |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 